Cefonicid

Summary

Cefonicid (CHEMBL1601) is an approved small-molecule antibacterial drug (ATC J01DC06); indicated across 2 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01DC06
• Indications: 2 conditions
• Chemistry: 542.6 Da · C18H18N6O8S3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1601
Name	Cefonicid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	43594
ChEBI	CHEBI:3491
ATC	J01DC06
Molecular formula	C18H18N6O8S3
Molecular weight	542.6
InChIKey	DYAIAHUQIPBDIP-AXAPSJFSSA-N

SMILES: C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)O)C(=O)O)CSC4=NN=NN4CS(=O)(=O)O

IUPAC name: (6R,7R)-7-[[(2R)-2-hydroxy-2-phenylacetyl]amino]-8-oxo-3-[[1-(sulfomethyl)tetrazol-5-yl]sulfanylmethyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

ChEBI definition: A cephalosporin bearing {[1-(sulfomethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and (R)-2-hydroxy-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Cefonicid, Cefonicide, Monocef, SID50112712, CEFONICID, cefonicid, Cefonicid (sodium)

Parent form; salt/anhydrous children: CHEMBL1201005, CHEMBL2105997

Patent coverage: 2,690 distinct patent families (10,456 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: 4’-phosphopantetheinyl transferase ffp, Sodium-dependent serotonin transporter.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).